Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VX-222 + telaprevir + ribavirin
- Development stage
- Unknown
- Lead developer
- Vertex
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VX-222 + telaprevir + ribavirin is an investigational triple combination therapy for chronic hepatitis C virus (HCV) infection, specifically genotype 1. VX-222 is a selective, non-nucleoside inhibitor of HCV NS5B polymerase, while telaprevir is a specific, reversible, covalent inhibitor of the HCV NS3/4A protease. Ribavirin is a nucleoside analog with broad-spectrum antiviral activity, commonly used as part of HCV treatment. The combination aims to target two essential viral enzymes, increasing the barrier to resistance and treatment efficacy. This regimen has been evaluated in phase 2 studies (notably the ZENITH trial), showing substantial antiviral activity and sustained virologic response, with improved tolerability when peginterferon is excluded[1][2][4][7].
- Other names
- telaprevir + ribavirin + VX-222
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)HCV RNA (Hepatitis C virus RNA)
Beyond the preview
Go deeper on VX-222 + telaprevir + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VX-222 + telaprevir + ribavirin.